Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.

* denotes publications from the CTD2 initiative that are results of intra-Network collaborations


June 11, 2020

Study highlights the usage of FDA-approved tyrosine kinase inhibitors for treating leukemia patients with neurotrophic receptor tyrosine kinase mutations.

June 01, 2020
Nature Chemical Biology

Integrated analysis of RNA-sequencing, proteomics, and phosphoproteomics data indicate doublecortin like kinase 1 (DCLK1) modulates proteins and pathways associated with cell motility in patient-derived pancreatic ductal adenocarcinoma (PDAC) organoids.

May 12, 2020
Nat Commun.

UCSF CTD2 scientists developed a multi-faceted testing framework and demonstrate that analysis of protein networks rather than a single gene identifies synthetic lethal candidates. These candidates are reproducible as they are dependent on genetic and cellular context.

May 08, 2020
Nat Commun.

p85β regulatory subunit of phosphatidylinositol 3-kinase upregulates tyrosine kinase, AXL, activating p110 subunit to induce PDK1/SGK3 signaling in PIK3R2-amplified ovarian cancer. These findings indicate that targeting AXL with small molecule inhibitors could be a potential therapeutic strategy.

May 04, 2020

Scientists discovered point mutations in the ErbB2 receptor in a small subset of hematologic malignancies. These point mutations are shown to be oncogenic in cytokine-independent cellular assay and sensitive to irreversible ErbB inhibitors.